LONDON, Sept. 23, 2015 /PRNewswire/ -- The ability to formulate injectable drugs to increase the duration of efficacy for a given dose and simultaneously reduce the dosing frequency addresses several important health care issues. Less frequent dosing is believed to improve patient safety, reduce the incidence of injection site complications and improve compliance with drug protocols. Sustained release formulations mitigate the bolus effect at the time of injection, and thus have a salutary influence on drug side effects. All of these advantages, along with the need for fewer patient caregiver visits (for practitioner-administered drugs) have a positive, downward impact on overall healthcare costs.
Currently approved sustained release injectables rely on a spectrum of branded formulation technologies to modulate the drug's release profile post-injection. Typically off-patent or generic drugs, they include drug therapies for almost a dozen major therapeutic segments, including neurological conditions, metabolic diseases, oncology, pain management and reproductive health. As the incidence and prevalence of chronic illnesses increases with the aging population, the attraction and interest in sustained release injectables will increase.
- Provides detailed analysis of sustained release injectable products, market segments, market dynamics and market demographics
- Analyzes therapeutic demand drivers and evaluates commercial sustained release injectables in eleven major therapeutic segments
- Charts sustained release product data and market share, and provides forecasts to 2022
- Profiles sustained release technology participants, their product development activities, business strategies, and corporate alliances and affiliations
Download the full report: https://www.reportbuyer.com/product/1973869/
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
For more information:
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48